ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ATXI Avenue Therapeutics Inc

1.31
-0.05 (-3.68%)
15 Feb 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Avenue Therapeutics Inc NASDAQ:ATXI NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.05 -3.68% 1.31 1.30 1.39 1.3897 1.3301 1.36 107,500 00:48:09

Avenue Therapeutics to Participate in Upcoming Investor Conferences

03/09/2024 1:30pm

GlobeNewswire Inc.


Avenue Therapeutics (NASDAQ:ATXI)
Historical Stock Chart


From Aug 2024 to Feb 2025

Click Here for more Avenue Therapeutics Charts.

Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in the following upcoming investor conferences:

H.C. Wainwright 26th Annual Global Investment ConferenceDate: Monday, September 9, 2024Location: New YorkFormat: Company Presentation and 1x1 Meetings

Lake Street Capital Markets BIG8 ConferenceDate: Thursday, September 12, 2024Location: New YorkFormat: 1x1 Meetings

The H.C. Wainwright company presentation will be available for on-demand viewing by conference attendees starting on September 9, 2024, at 7:00 a.m. ET.

About Avenue TherapeuticsAvenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. It is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABAA α2, α3 receptor positive allosteric modulator for CNS diseases, and IV tramadol for the management of acute postoperative pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.avenuetx.com.

Contact: Jaclyn Jaffe Avenue Therapeutics, Inc. (781) 652-4500ir@avenuetx.com

1 Year Avenue Therapeutics Chart

1 Year Avenue Therapeutics Chart

1 Month Avenue Therapeutics Chart

1 Month Avenue Therapeutics Chart

Your Recent History

Delayed Upgrade Clock